Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism

Ascendis Pharma A/S ASND has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH Forward Trial evaluating TransCon PTH in adult subjects with hypoparathyroidism (HP).
Key Findings of the Preliminary OLE Results:
- Fifty-eight subjects continue in the open-label extension beyond 58 weeks as of May 7.
- Data showed established physiologic calcium metabolism based upon normalization of 24-hour urine calcium excretion and a downward trend toward mid-normal levels in bone markers without using therapeutic calcium and vitamin D supplementation.
- No treatment-related serious or severe adverse events occurred, and no treatment-emergent adverse events led to discontinuation of the study drug.
In addition to PaTH Forward, Ascendis Pharma is conducting the PaTHway Phase 3 trial in North America and Europe, evaluating the safety, tolerability, and efficacy of TransCon PTH.
Topline results are expected by the end of this year.
TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) designed to restore PTH at physiologic levels 24 hours each day.
Price Action: ASND shares closed 2% lower at $130.07 on Monday.